Total Payments
$1,848
2024 Payments
$242.61
Companies
21
Transactions
60
Medicare Patients
6,451
Medicare Billing
$396,224
Payment Breakdown by Category
Food & Beverage$1,547 (83.7%)
Education$300.93 (16.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,547 | 56 | 83.7% |
| Education | $300.93 | 4 | 16.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Galt Pharmaceuticals, LLC | $518.60 | 1 | $0 (2023) |
| Astellas Pharma US Inc | $328.00 | 5 | $0 (2023) |
| Novo Nordisk Inc | $197.92 | 18 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $99.79 | 6 | $0 (2024) |
| Atland Pharmaceuticals, LLC | $80.07 | 1 | $0 (2024) |
| Lilly USA, LLC | $70.67 | 5 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $63.60 | 1 | $0 (2021) |
| ABBVIE INC. | $60.54 | 4 | $0 (2023) |
| PFIZER INC. | $55.27 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $242.61 | 11 | AstraZeneca Pharmaceuticals LP ($85.73) |
| 2023 | $1,100 | 28 | Galt Pharmaceuticals, LLC ($518.60) |
| 2022 | $198.99 | 6 | Boehringer Ingelheim Pharmaceuticals, Inc. ($125.00) |
| 2021 | $306.54 | 15 | Biohaven Pharmaceuticals, Inc. ($63.60) |
All Payment Transactions
60 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: PSYCHIATRY | ||||||
| 05/30/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Oncology | ||||||
| 05/04/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/18/2024 | Atland Pharmaceuticals, LLC | ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE (Drug), TOLMETIN SODIUM | Food and Beverage | In-kind items and services | $80.07 | General |
| Category: Pain | ||||||
| 03/13/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: Respiratory | ||||||
| 02/29/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: Respiratory | ||||||
| 02/21/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: Inflammation | ||||||
| 02/08/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: Obesity | ||||||
| 01/18/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: Respiratory | ||||||
| 01/13/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/05/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/07/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/01/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: Diabetes | ||||||
| 10/24/2023 | Astellas Pharma US Inc | — | Education | In-kind items and services | $61.00 | General |
| 10/19/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: Obesity | ||||||
| 10/06/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $5.74 | General |
| Category: Diabetes | ||||||
| 10/02/2023 | Astellas Pharma US Inc | — | Education | In-kind items and services | $94.99 | General |
| 10/02/2023 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.99 | General |
| 10/02/2023 | Astellas Pharma US Inc | — | Education | In-kind items and services | $64.95 | General |
| 09/29/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $6.37 | General |
| Category: Diabetes | ||||||
| 09/21/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $27.07 | General |
| Category: Biological | ||||||
| 09/01/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: Obesity | ||||||
| 08/23/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: Diabetes | ||||||
| 08/18/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.36 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,935 | 3,731 | $372,681 | $99,970 |
| 2022 | 20 | 1,786 | 3,729 | $420,533 | $114,553 |
| 2021 | 19 | 1,514 | 3,186 | $418,146 | $111,842 |
| 2020 | 17 | 1,216 | 2,275 | $298,098 | $69,860 |
Total Patients
6,451
Total Services
12,921
Medicare Billing
$396,224
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 341 | 681 | $181,146 | $43,959 | 24.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 246 | 434 | $77,686 | $20,516 | 26.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 178 | 178 | $50,018 | $18,389 | 36.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 198 | 493 | $15,283 | $3,743 | 24.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 31 | 36 | $3,420 | $2,012 | 58.8% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 131 | 131 | $6,681 | $1,897 | 28.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $9,816 | $1,616 | 16.5% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 98 | 98 | $4,998 | $1,419 | 28.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 17 | 17 | $2,329 | $1,347 | 57.8% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 16 | 16 | $2,352 | $1,151 | 48.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 36 | 36 | $1,140 | $1,026 | 90.0% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 121 | 152 | $2,128 | $769.25 | 36.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 48 | 56 | $2,520 | $533.12 | 21.2% |
| 81002 | Urinalysis, manual test | Office | 2023 | 76 | 132 | $1,452 | $450.12 | 31.0% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 20 | 20 | $480.00 | $434.76 | 90.6% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 123 | 208 | $3,120 | $215.77 | 6.9% |
| 69209 | Removal of impacted ear wax by washing | Office | 2023 | 23 | 24 | $744.00 | $185.20 | 24.9% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 70 | 356 | $5,340 | $127.58 | 2.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 15 | 15 | $780.00 | $127.54 | 16.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 123 | 624 | $1,248 | $51.95 | 4.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 366 | 894 | $237,804 | $59,680 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 225 | 372 | $66,588 | $18,992 | 28.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 157 | 157 | $44,117 | $16,606 | 37.6% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 16 | 16 | $10,320 | $4,449 | 43.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 44 | 44 | $17,996 | $3,913 | 21.7% |
About Wendy Vix, NP
Wendy Vix, NP is a Family healthcare provider based in Lillian, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2019. The National Provider Identifier (NPI) number assigned to this provider is 1639738081.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Wendy Vix, NP has received a total of $1,848 in payments from pharmaceutical and medical device companies, with $242.61 received in 2024. These payments were reported across 60 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($1,547).
As a Medicare-enrolled provider, Vix has provided services to 6,451 Medicare beneficiaries, totaling 12,921 services with total Medicare billing of $396,224. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Lillian, AL
- Active Since 06/10/2019
- Last Updated 09/12/2022
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1639738081
Products in Payments
- Orphengesic Forte (Drug) $518.60
- Ozempic (Drug) $88.45
- ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE (Drug) $80.07
- NURTEC ODT (Drug) $63.60
- VRAYLAR (Drug) $60.54
- Wegovy (Drug) $56.73
- Rybelsus (Drug) $52.74
- FARXIGA (Drug) $50.92
- Yupelri (Drug) $49.49
- AIRSUPRA (Drug) $48.87
- ELIQUIS (Drug) $40.07
- NEXLETOL (Drug) $35.39
- Otezla (Drug) $31.13
- MOUNJARO (Drug) $30.63
- Veozah (Drug) $27.07
- INTELLIS ADAPTIVESTIM (Device) $24.87
- TRULICITY (Drug) $24.32
- Epclusa (Drug) $21.25
- REXULTI (Drug) $17.83
- NUZYRA (Drug) $17.56
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.